By specifically inhibiting the cyclin D-CDK4/6-Rb pathway, CDK4/6 inhibitors overcome endocrine resistance in HR+ breast cancer, which successfully delays the progression of the disease (Roberto et al. 2021; Huang et al. 2022). The gene discussed is RB1; the disease is breast cancer.